The role of novel red yeast rice formulation to modulate lipid metabolism and reduce dyslipidemia and vascular disease in the JCR:LA-cp rat

• Author / Creator

  Wu, Sheng

• Liver derived low-density lipoprotein and intestinal derived chylomicron remnant are contributors to dyslipidemia and cardiovascular disease (CVD). In clinical practice, the most common medication to reduce fasting LDL-cholesterol is statins. However, for many individuals prescribed statins, a substantial ‘residual risk’ of CVD remains. Therefore, effective nutraceutical approaches that have multiple targets to lower cholesterol secreted by both the liver and the intestine remain attractive.
  The objective was to assess the lipid lowering efficacy of novel formulations: chitin-glucan, phytosterol, the red yeast rice, using a rodent model of dyslipidemia.
  It was observed that these active ingredients all independently reduced fasting plasma lipids. Further, the combination of these ingredients, with 1mg/kg red yeast rice, was the most effective at reducing both fasting and non-fasting plasma lipids. The findings provide pre-clinical support for the combined use of these ingredients as a nutraceutical alternative to classic lipid lowering pharmacotherapies.

• Subjects / Keywords

  • Red yeast rice
  • Dyslipidemia
  • Chylomicron remnant

• Graduation date

  Spring 2013

• Type of Item

  Thesis

• Degree

  Master of Science

• DOI

  https://doi.org/10.7939/R3XK84X3B

• License

  This thesis is made available by the University of Alberta Libraries with permission of the copyright owner solely for non-commercial purposes. This thesis, or any portion thereof, may not otherwise be copied or reproduced without the written consent of the copyright owner, except to the extent permitted by Canadian copyright law.